RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 Does Aspirin's Ability to Improve CRC Prognosis Depend on PIK3CA Mutation Status?
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 22
SP 8
OP 9
DO 10.1177/155989771422003
UL http://mdc.sagepub.com/content/14/22/8.abstract
AB Aspirin may be an effective adjuvant treatment for patients with cancer; this has been suggested by long-term follow-up of randomized trials that were originally designed to determine the vascular effects of aspirin. This article discusses Add-Aspirin, a Phase 3 double-blind multicenter trial that will determine whether taking low-dose aspirin on a regular basis will improve the prognosis of patients who have recently undergone primary curative treatment for nonmetastatic colorectal, gastroesophageal, breast, or prostate cancer.